Elvire Pons‐Tostivint

机构：Centre Hospitalier Universitaire de Nantes, Nantes Université · ORCID：0000-0003-4478-0523

发表论文 103 篇 · 总被引 2721 次 · h-index 24

代表论文

• Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study (2025 · Journal of Clinical Oncology · 被引 115)
• A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC (2025 · Journal of Thoracic Oncology · 被引 49)
• Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC (2025 · Journal of Thoracic Oncology · 被引 22)
• Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections) (2025 · Knee Surgery Sports Traumatology Arthroscopy · 被引 12)
• Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study (2025 · Journal of Thoracic Oncology · 被引 10)
• Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer (2025 · ESMO Open · 被引 5)